BR0306846A - Produto substituto do sangue, composição útil como um substituto do sangue, método para fazer um produto substituto do sangue, e, método de uso de um produto substituto do sangue para fornecer oxigênio a um tecido - Google Patents
Produto substituto do sangue, composição útil como um substituto do sangue, método para fazer um produto substituto do sangue, e, método de uso de um produto substituto do sangue para fornecer oxigênio a um tecidoInfo
- Publication number
- BR0306846A BR0306846A BR0306846-3A BR0306846A BR0306846A BR 0306846 A BR0306846 A BR 0306846A BR 0306846 A BR0306846 A BR 0306846A BR 0306846 A BR0306846 A BR 0306846A
- Authority
- BR
- Brazil
- Prior art keywords
- blood substitute
- substitute product
- making
- product
- blood
- Prior art date
Links
- 239000003633 blood substitute Substances 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract 4
- 229910052760 oxygen Inorganic materials 0.000 title abstract 4
- 239000001301 oxygen Substances 0.000 title abstract 4
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 239000010836 blood and blood product Substances 0.000 abstract 1
- 229940125691 blood product Drugs 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34774102P | 2002-01-11 | 2002-01-11 | |
US10/114,400 US20030153491A1 (en) | 2002-01-11 | 2002-04-01 | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
PCT/US2003/000696 WO2003059363A1 (en) | 2002-01-11 | 2003-01-10 | Methods and compositions for oxygen transport comprising a high oyzgen affinity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0306846A true BR0306846A (pt) | 2004-12-07 |
Family
ID=26812138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0306846-3A BR0306846A (pt) | 2002-01-11 | 2003-01-10 | Produto substituto do sangue, composição útil como um substituto do sangue, método para fazer um produto substituto do sangue, e, método de uso de um produto substituto do sangue para fornecer oxigênio a um tecido |
Country Status (15)
Country | Link |
---|---|
US (3) | US20030153491A1 (de) |
EP (1) | EP1465643B1 (de) |
JP (2) | JP5149480B2 (de) |
KR (1) | KR100964604B1 (de) |
CN (2) | CN1630527B (de) |
AT (1) | ATE382358T1 (de) |
AU (1) | AU2003207504B2 (de) |
BR (1) | BR0306846A (de) |
CA (1) | CA2473662C (de) |
DE (1) | DE60318388T2 (de) |
DK (1) | DK1465643T3 (de) |
ES (1) | ES2299686T3 (de) |
MX (1) | MXPA04006733A (de) |
PT (1) | PT1465643E (de) |
WO (1) | WO2003059363A1 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
DE60336018D1 (de) * | 2002-12-23 | 2011-03-24 | Einstein Coll Med | Nicht-hypertensive pegylierte hämoglobine und deren herstellungsverfahren |
KR101025143B1 (ko) * | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드-종결 중합체 |
US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
WO2005056636A2 (en) | 2003-12-03 | 2005-06-23 | Nektar Therapeutics Al, Corporation | Method of preparing maleimide functionalized polymers |
CN101039684A (zh) * | 2004-08-31 | 2007-09-19 | 桑格特公司 | 使用氧载体组合物增强血液动力稳定性的方法 |
US8455437B2 (en) * | 2005-02-04 | 2013-06-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Method to predict and prevent oxygen-induced inflammatory tissue injury |
WO2006096774A2 (en) * | 2005-03-07 | 2006-09-14 | Sangart, Inc. | Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers |
US20090215670A1 (en) * | 2005-05-11 | 2009-08-27 | Acharya Seetharama A | Site specific pegylated hemoglobin, method of preparing same, and uses thereof |
US8741832B2 (en) * | 2005-06-10 | 2014-06-03 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated albumin and uses thereof |
US8071546B2 (en) * | 2005-06-10 | 2011-12-06 | La Jolla Bioengineering Institute | Uses of pegylated albumin |
KR101334541B1 (ko) | 2005-07-19 | 2013-11-28 | 넥타르 테라퓨틱스 | 중합체 말레이미드를 제조하는 방법 |
EP2474554A3 (de) | 2006-05-22 | 2012-10-03 | The Regents of The University of California | Zusammensetzungen und Verfahren zur Freisetzung von Sauerstoff |
US7504377B2 (en) * | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
CN101158676B (zh) * | 2006-12-31 | 2011-12-14 | 重庆大学 | 一种评价血液及其代用品携氧、释氧功能的分析方法及装置 |
US20090191244A1 (en) | 2007-09-27 | 2009-07-30 | Children's Medical Center Corporation | Microbubbles and methods for oxygen delivery |
US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
US10172949B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
AU2010258752B2 (en) * | 2009-06-09 | 2015-07-09 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
US9114109B2 (en) * | 2009-06-16 | 2015-08-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | Five-coordinate neuroglobin and use thereof as a blood substitute |
US8273857B2 (en) * | 2009-09-22 | 2012-09-25 | Jen-Chang Hsia | Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine |
US20130041134A1 (en) * | 2009-11-05 | 2013-02-14 | Sangart ,Inc. | Methods for preparing polyethylene glycol maleimide using n-(2-hydroxyethyl) maleimide as a starting material |
AU2011220885A1 (en) * | 2010-02-25 | 2012-09-06 | Sangart, Inc. | Methods for preparing PEG-hemoglobin conjugates using reduced reactant ratios |
US7989593B1 (en) | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
US8048856B1 (en) | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
US7932356B1 (en) | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
PT2661275T (pt) * | 2011-01-07 | 2019-04-24 | Poseida Therapeutics Inc | Composições e métodos para a entrega a tumores de agentes ligantes de elevada afinidade para o oxigénio |
US20120196270A1 (en) * | 2011-02-02 | 2012-08-02 | Sangart, Inc. | Methods for preserving an organ for transplantation using a hemoglobin-carbon monoxide complex |
EP2682407B1 (de) | 2011-03-01 | 2016-09-14 | Chuo University | Hämoglobin-albumin-komplex sowie künstlicher plasmaexpander und künstlicher sauerstoffträger damit |
US8084581B1 (en) | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
WO2013070592A1 (en) * | 2011-11-07 | 2013-05-16 | The General Hospital Corporation | Treatment of red blood cells |
CN104379160A (zh) * | 2012-03-29 | 2015-02-25 | 桑加特公司 | 双阿司匹林交联聚乙二醇化血红蛋白 |
WO2013151776A1 (en) | 2012-04-03 | 2013-10-10 | Sangart, Inc. | Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins |
US10357450B2 (en) | 2012-04-06 | 2019-07-23 | Children's Medical Center Corporation | Process for forming microbubbles with high oxygen content and uses thereof |
EP3922643A1 (de) | 2013-01-07 | 2021-12-15 | Omniox, Inc. | Polymere formen von h-nox-proteinen |
US10577554B2 (en) | 2013-03-15 | 2020-03-03 | Children's Medical Center Corporation | Gas-filled stabilized particles and methods of use |
KR102238718B1 (ko) * | 2013-03-15 | 2021-04-12 | 쉰들러, 윌리엄 | 폴리알킬렌 산화물 발레르산염 헤모글로빈 접합체 |
US10456452B2 (en) | 2015-07-02 | 2019-10-29 | Poseida Therapeutics, Inc. | Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles |
CN105497894B (zh) * | 2015-12-21 | 2019-01-04 | 中国科学院深圳先进技术研究院 | 用于肿瘤光动力治疗的血红蛋白-光敏剂试剂及其应用 |
US20200276265A1 (en) | 2016-02-16 | 2020-09-03 | Omniox, Inc. | Modulation hypoxia associated with stroke |
US11213594B2 (en) | 2016-04-29 | 2022-01-04 | Poseida Therapeutics, Inc. | Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids |
JP7016124B2 (ja) | 2016-07-06 | 2022-02-04 | 学校法人 中央大学 | 虚血性疾患の治療剤 |
ES2651717B1 (es) * | 2016-07-26 | 2018-11-16 | Lara OLLER DUQUE | Solución acuosa cristaloide isotónica |
US11147890B2 (en) | 2017-02-28 | 2021-10-19 | Children's Medical Center Corporation | Stimuli-responsive particles encapsulating a gas and methods of use |
EP3836911A1 (de) | 2018-08-15 | 2021-06-23 | Omniox, Inc. | H-nox-proteine zur behandlung kardiovaskulärer und pulmonaler störungen |
CN111499732B (zh) * | 2020-04-22 | 2022-05-13 | 中国科学院过程工程研究所 | 一种基于双重化学修饰的血红蛋白氧载体及其制备方法和应用 |
WO2021261712A1 (en) * | 2020-06-26 | 2021-12-30 | Sunbio, Inc. | Hemoglobin derivative co-conjugated with fatty acid-linked peg and alkoxy peg as a blood substitute |
CN114617957B (zh) * | 2022-03-10 | 2024-01-16 | 中国人民解放军军事科学院军事医学研究院 | 羟乙基淀粉血红蛋白偶联物及其制备方法与应用 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3507146A (en) * | 1968-02-09 | 1970-04-21 | Webb James E | Method and system for respiration analysis |
US3956259A (en) * | 1973-01-30 | 1976-05-11 | Baxter Laboratories, Inc. | Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate |
US3925344A (en) * | 1973-04-11 | 1975-12-09 | Community Blood Council | Plasma protein substitute |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2449885C3 (de) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat |
US4001200A (en) * | 1975-02-27 | 1977-01-04 | Alza Corporation | Novel polymerized, cross-linked, stromal-free hemoglobin |
US4001401A (en) * | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
US4061736A (en) * | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
US4053590A (en) * | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
CA1055932A (en) * | 1975-10-22 | 1979-06-05 | Hematech Inc. | Blood substitute based on hemoglobin |
GB1578776A (en) * | 1976-06-10 | 1980-11-12 | Univ Illinois | Hemoglobin liposome and method of making the same |
JPS5329908A (en) * | 1976-08-27 | 1978-03-20 | Green Cross Corp:The | Immobilized haptoglobin preparation |
US4209300A (en) * | 1978-09-25 | 1980-06-24 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Hemoglobin-oxygen equilibrium curve analyzer |
JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5716815A (en) * | 1980-07-02 | 1982-01-28 | Ajinomoto Co Inc | Oxygen transporting agent for artificial blood |
US4401652A (en) * | 1980-12-31 | 1983-08-30 | Allied Corporation | Process for the preparation of stroma-free hemoglobin solutions |
JPS57206622A (en) * | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
US4532130A (en) * | 1981-07-06 | 1985-07-30 | Rush-Presbyterian-St. Luke's Medical Center | Preparation of synthetic frythrocytes |
DE3130770C2 (de) * | 1981-08-04 | 1986-06-19 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Gewinnung von hepatitissicheren, sterilen, pyrogenfreien und stromafreien Hämoglobinlösungen |
US4473496A (en) * | 1981-09-14 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Intramolecularly crosslinked hemoglobin |
DE3144705C2 (de) * | 1981-11-11 | 1983-12-08 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat |
CH650647A5 (de) * | 1982-12-10 | 1985-08-15 | Knorr Naehrmittel Ag | Lagerfaehiges, zu einer dessert-mousse aufschlagbares produkt und verfahren zu dessen herstellung. |
US4529719A (en) * | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
US4473494A (en) * | 1983-05-04 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Preparation of stroma-free, non-heme protein-free hemoglobin |
GB8328917D0 (en) * | 1983-10-28 | 1983-11-30 | Fisons Plc | Blood substitute |
US5281579A (en) * | 1984-03-23 | 1994-01-25 | Baxter International Inc. | Purified virus-free hemoglobin solutions and method for making same |
US4831012A (en) * | 1984-03-23 | 1989-05-16 | Baxter International Inc. | Purified hemoglobin solutions and method for making same |
DE3412144A1 (de) * | 1984-03-31 | 1985-10-10 | Biotest Pharma GmbH, 6000 Frankfurt | Verfahren zur herstellung hochgereinigter, stromafreier, hepatitissicherer human- und tierhaemoglobinloesungen |
US4738952A (en) * | 1984-04-27 | 1988-04-19 | Synthetic Blood Corporation | Substitute for human blood and a method of making the same |
US4600531A (en) * | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
US4598064A (en) * | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
US4584130A (en) | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
EP0206448B1 (de) * | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist |
US4987154A (en) * | 1986-01-14 | 1991-01-22 | Alliance Pharmaceutical Corp. | Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use |
US5080885A (en) * | 1986-01-14 | 1992-01-14 | Alliance Pharmaceutical Corp. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
US5077036A (en) * | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
US5684050A (en) * | 1986-01-24 | 1997-11-04 | Hemagen/Pfc | Stable emulsions of highly fluorinated organic compounds |
US5464814A (en) * | 1986-06-20 | 1995-11-07 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
US5194590A (en) * | 1986-06-20 | 1993-03-16 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
DE3620873A1 (de) * | 1986-06-21 | 1987-12-23 | Rau Guenter | Vorrichtung zur bestimmung des partialdruckes von in einem fluid geloesten gasen und gasgemischen |
US4911929A (en) * | 1986-08-29 | 1990-03-27 | The United States Of America As Represented By The Secretary Of The Navy | Blood substitute comprising liposome-encapsulated hemoglobin |
DE3636590A1 (de) * | 1986-10-28 | 1988-05-26 | Braun Melsungen Ag | Blutersatzmittel |
US5084558A (en) * | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
CA1312009C (en) * | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
GB8710598D0 (en) * | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
US5449759A (en) * | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
GB8711614D0 (en) * | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
US4861867A (en) * | 1988-02-03 | 1989-08-29 | Baxter International, Inc. | Purified hemoglobin solutions and method for making same |
US4900780A (en) * | 1988-05-25 | 1990-02-13 | Masonic Medical Research Laboratory | Acellular resuscitative fluid |
CA1338244C (en) * | 1988-08-17 | 1996-04-09 | Xiang-Fu Wu | Purification of hemoglobin and methemoglobin by bioselective elution |
US5061688A (en) * | 1988-08-19 | 1991-10-29 | Illinois Institute Of Technology | Hemoglobin multiple emulsion |
US5128452A (en) * | 1989-04-19 | 1992-07-07 | Baxter International Inc. | Process for the production of crosslinked hemoglobin in the presence of sodium tripolyphosphate |
US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
US5599907A (en) * | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
US5312808A (en) * | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
US5386014A (en) * | 1989-11-22 | 1995-01-31 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute |
US5650388A (en) * | 1989-11-22 | 1997-07-22 | Enzon, Inc. | Fractionated polyalkylene oxide-conjugated hemoglobin solutions |
US5478806A (en) * | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
US5041615A (en) * | 1989-12-05 | 1991-08-20 | Baxter International Inc. | Preparation of bis(salicyl) diesters |
US5239061A (en) * | 1990-06-20 | 1993-08-24 | Research Corporation Technologies, Inc. | Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin |
US5352773A (en) * | 1990-08-06 | 1994-10-04 | Baxter International Inc. | Stable hemoglobin based composition and method to store same |
US5248766A (en) * | 1990-08-17 | 1993-09-28 | Baxter International Inc. | Oxirane-modified hemoglobin based composition |
US5114932A (en) * | 1990-11-30 | 1992-05-19 | Runge Thomas M | Hyperosmolar oxyreplete hemosubstitute |
US5234555A (en) * | 1991-02-05 | 1993-08-10 | Ibbott Jack Kenneth | Method and apparatus for ionizing fluids utilizing a capacitive effect |
CA2066374C (en) * | 1991-04-19 | 2002-01-29 | Paul E. Segall | Solution for perfusing primates |
US5295944A (en) * | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
US5250665A (en) * | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
US5349054A (en) * | 1991-08-15 | 1994-09-20 | Duke University | Activated benzenepentacarboxylate-crosslinked low oxygen affinity hemoglobin |
US5334705A (en) * | 1991-08-15 | 1994-08-02 | Duke University | Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin |
US5334706A (en) * | 1992-01-30 | 1994-08-02 | Baxter International | Administration of low dose hemoglobin to increase perfusion |
US5200323A (en) * | 1992-01-31 | 1993-04-06 | Mcgill University | In vitro method to determine the safety of modified hemoglobin blood substitutes for human prior to clinical use |
US5296466A (en) * | 1992-02-19 | 1994-03-22 | Board Of Regents, The University Of Texas System | Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein |
US5344393A (en) * | 1992-02-28 | 1994-09-06 | Alliance Pharmaceutical Corp. | Use of synthetic oxygen carriers to facilitate oxygen delivery |
US5264555A (en) | 1992-07-14 | 1993-11-23 | Enzon, Inc. | Process for hemoglobin extraction and purification |
US5628930A (en) * | 1992-10-27 | 1997-05-13 | Alliance Pharmaceutical Corp. | Stabilization of fluorocarbon emulsions |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
US5635538A (en) * | 1993-03-16 | 1997-06-03 | Alliance Pharmaceutical Corp. | Fluorocarbon emulsions with reduced pulmonary gas-trapping properties |
NZ262349A (en) * | 1993-03-16 | 1996-05-28 | Hemosol Inc | Chemically modifying haemoglobin by crosslinking with a polyaldehyde produced by ring opening oxidation of a saccharide; for use in a blood substitute |
US5554638A (en) * | 1993-05-24 | 1996-09-10 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
US5612310A (en) * | 1993-05-24 | 1997-03-18 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
US5407428A (en) * | 1993-06-04 | 1995-04-18 | Biotime, Inc. | Solutions for use as plasma expanders and substitutes |
WO1994028950A1 (en) * | 1993-06-04 | 1994-12-22 | Biotime, Inc. | Plasma-like solution |
US5578564A (en) * | 1993-07-23 | 1996-11-26 | Somatogen, Inc. | Nickel-free hemoglobin and methods for producing such hemoglobin |
TW381022B (en) * | 1993-08-16 | 2000-02-01 | Hsia Jen Chang | Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute |
CA2106612C (en) * | 1993-09-21 | 2001-02-06 | Diana Pliura | Displacement chromatography process |
US5545328A (en) * | 1993-09-21 | 1996-08-13 | Hemosol Inc. | Purification of hemoglobin by displacement chromatography |
US5631219A (en) * | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
US5585484A (en) * | 1995-04-19 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Hemoglobin crosslinkers |
US5525630A (en) * | 1995-06-01 | 1996-06-11 | Allos Therapeutics, Inc. | Treatment for carbon monoxide poisoning |
DE69831248T2 (de) * | 1997-02-28 | 2006-04-13 | The Regents Of The University Of California, Oakland | Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen |
US5814601A (en) * | 1997-02-28 | 1998-09-29 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
ATE270431T1 (de) * | 1997-10-17 | 2004-07-15 | Univ California | System und verfahren zum charakterisieren von gastransporteigenschaften |
US5985825A (en) * | 1998-02-28 | 1999-11-16 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
CA2233725A1 (en) * | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
US7271145B2 (en) * | 2002-01-11 | 2007-09-18 | Sangart, Inc. | Methods and compositions for oxygen transport comprising modified hemoglobin in plasma |
EP1472280A4 (de) * | 2002-01-11 | 2005-09-21 | Sangart Inc | Verfahren und zusammen setzungen zum sauerstofftransport, umfassend einen sauerstoffträger und ein kristalloid in einer hypertonen lösung |
DE60336018D1 (de) * | 2002-12-23 | 2011-03-24 | Einstein Coll Med | Nicht-hypertensive pegylierte hämoglobine und deren herstellungsverfahren |
-
2002
- 2002-04-01 US US10/114,400 patent/US20030153491A1/en not_active Abandoned
-
2003
- 2003-01-10 BR BR0306846-3A patent/BR0306846A/pt not_active Application Discontinuation
- 2003-01-10 KR KR1020047010847A patent/KR100964604B1/ko active IP Right Grant
- 2003-01-10 DK DK03705713T patent/DK1465643T3/da active
- 2003-01-10 EP EP03705713A patent/EP1465643B1/de not_active Expired - Lifetime
- 2003-01-10 CN CN038036487A patent/CN1630527B/zh not_active Expired - Fee Related
- 2003-01-10 CN CN2013100910214A patent/CN103203013A/zh active Pending
- 2003-01-10 JP JP2003559525A patent/JP5149480B2/ja not_active Expired - Fee Related
- 2003-01-10 ES ES03705713T patent/ES2299686T3/es not_active Expired - Lifetime
- 2003-01-10 US US10/340,141 patent/US6844317B2/en not_active Expired - Lifetime
- 2003-01-10 MX MXPA04006733A patent/MXPA04006733A/es active IP Right Grant
- 2003-01-10 DE DE60318388T patent/DE60318388T2/de not_active Expired - Lifetime
- 2003-01-10 PT PT03705713T patent/PT1465643E/pt unknown
- 2003-01-10 AU AU2003207504A patent/AU2003207504B2/en not_active Ceased
- 2003-01-10 WO PCT/US2003/000696 patent/WO2003059363A1/en active IP Right Grant
- 2003-01-10 AT AT03705713T patent/ATE382358T1/de active
- 2003-01-10 CA CA002473662A patent/CA2473662C/en not_active Expired - Lifetime
-
2004
- 2004-08-24 US US10/925,067 patent/US6974795B2/en not_active Expired - Lifetime
-
2010
- 2010-03-09 JP JP2010052387A patent/JP2010138197A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2003207504B2 (en) | 2007-05-24 |
DK1465643T3 (da) | 2008-05-13 |
EP1465643B1 (de) | 2008-01-02 |
CN103203013A (zh) | 2013-07-17 |
MXPA04006733A (es) | 2005-12-05 |
EP1465643A1 (de) | 2004-10-13 |
JP2005515225A (ja) | 2005-05-26 |
US6844317B2 (en) | 2005-01-18 |
CN1630527B (zh) | 2013-04-24 |
KR100964604B1 (ko) | 2010-06-21 |
US20030162693A1 (en) | 2003-08-28 |
WO2003059363A1 (en) | 2003-07-24 |
CA2473662A1 (en) | 2003-07-24 |
ES2299686T3 (es) | 2008-06-01 |
CA2473662C (en) | 2009-12-22 |
US20030153491A1 (en) | 2003-08-14 |
US20050026816A1 (en) | 2005-02-03 |
CN1630527A (zh) | 2005-06-22 |
DE60318388D1 (de) | 2008-02-14 |
ATE382358T1 (de) | 2008-01-15 |
JP5149480B2 (ja) | 2013-02-20 |
KR20040081451A (ko) | 2004-09-21 |
PT1465643E (pt) | 2008-03-27 |
JP2010138197A (ja) | 2010-06-24 |
EP1465643A4 (de) | 2004-10-20 |
AU2003207504A1 (en) | 2003-07-30 |
DE60318388T2 (de) | 2008-12-24 |
US6974795B2 (en) | 2005-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0306846A (pt) | Produto substituto do sangue, composição útil como um substituto do sangue, método para fazer um produto substituto do sangue, e, método de uso de um produto substituto do sangue para fornecer oxigênio a um tecido | |
BR0211888A (pt) | Materiais e métodos para promoção de reparo de tecido nervoso | |
BRPI0416292A (pt) | composições estabilizadas compreendendo probióticos | |
BR9809921A (pt) | Método para admistração de composição de microorganismos viáveis para aves domésticas | |
PT831882E (pt) | Composicoes de segmentos de fibra de colagenio reconstituido e metodos de preparacao das mesmas | |
BRPI0518050A (pt) | composição para debridamento a partir da bromelina e métodos para produção da mesma | |
RS20050066A (en) | Aqueous 2,6-diisopropylphenol pharmaceutical compositions | |
AU2003275958A1 (en) | Muteins of tear lipocalin | |
MXPA03006688A (es) | Portador con fibrinogeno solido y trombina solida. | |
ATE448686T1 (de) | Actriib-fusionspolypeptide und verwendungen dafür | |
PT1104294E (pt) | Composicoes e metodos de tratamento da proliferacao celular anormal | |
ATE264093T1 (de) | Sojazubereitungen und deren verwendung zur gesundheitsförderung | |
NO20031159D0 (no) | Melkesyrebakterier som er i stand til å redusere et individs tendens til åutvikle allergiske reaksjoner | |
BRPI0514411A (pt) | formulação, e, método de produzir uma formulação | |
EP1387614A4 (de) | Verfahren zur herstellung einer gereinigten shilajit-zusammensetzung aus nativem shilajit | |
BR9810832B1 (pt) | composição farmacêutica contendo como princìpios ativos vitamina d associada a um sal de cálcio, e, processos para a preparação de uma composição farmacêutica, para o tratamento de deficiências nutricionais de cálcio e vitamina d na velhice e para reduzir a perda de tecido ósseo ligada à idade e para evitar fraturas femurais e outras fraturas não vertebrais. | |
NO20013744D0 (no) | Fremgangsmåter og blandinger for heling og reparasjon av leddbrusk | |
BR9702144A (pt) | Compostos propinil biaromáticos composição farmacêutica composição cosmética e utilização de uma composição cosmética | |
EE200100125A (et) | TAN-1057 derivaadid | |
DE50207740D1 (de) | Verwendung von phosphatidylserin zur behandlung des aufmerksamkeits-defizit-syndroms (adhs) | |
TR200100896T2 (tr) | İkameli propanol türevleri, imalat yöntemleri, bileşimleri içeren ilaçlar, kullanımları | |
ATE211482T1 (de) | Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend | |
CN114686005A (zh) | 一种胶原蛋白与左旋聚乳酸共混物 | |
WO2007027092A3 (en) | Oral composition for moisturising skin | |
DE69930419D1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 35/12 , A61K 35/14 , A61K 38/00 , A61K 38/16 Ipc: A61K 38/42 (2006.01), A61P 7/06 (2006.01) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |